The phase III clinical trial will involve 35,000 people aged 18 and over from several countries and will examine the efficacy of the vaccine against the original strain of the virus as well as the B.1.351 variant, first detected in South Africa.
“Recent scientific evidence shows that antibodies created against the B.1.351 variant can provide broad cross-protection against other more transmissible variants,” the two companies said in a statement.
The clinical studies to be launched in the coming weeks will examine the protection offered by the vaccine when it is administered as a second dose after a first injection with another vaccine.
“We are encouraged to see the first vaccinations begin to take place in such an important and crucial Phase 3 study because we believe our unique technology platform will provide a clinically relevant vaccine option,” said Thomas Triomphe, global manager of Sanofi Pasteur. .